TVTX Travere Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: TVTX

Price (delayed)

$6.26

Market cap

$476.38M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.5

Enterprise value

$822.98M

Travere Therapeutics is a biopharmaceutical company that comes together every day to help patients, families and caregivers of all backgrounds as they navigate life with a rare disease. On this ...

Highlights
The company's EPS has surged by 66% YoY but it fell by 2.7% QoQ
TVTX's net income has surged by 60% year-on-year but it is down by 28% since the previous quarter
The quick ratio has decreased by 29% from the previous quarter
TVTX's equity is down by 28% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www..travere.com
Peers: OPTN OPK ORGO

Key stats

What are the main financial stats of TVTX
Market
Shares outstanding
76.1M
Market cap
$476.38M
Enterprise value
$822.98M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.34
Price to sales (P/S)
3.2
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.67
Earnings
Revenue
$145.24M
EBIT
-$99.84M
EBITDA
-$61.31M
Free cash flow
-$322.28M
Per share
EPS
-$1.5
Free cash flow per share
-$4.34
Book value per share
$2.67
Revenue per share
$1.96
TBVPS
$9.22
Balance sheet
Total assets
$788.91M
Total liabilities
$588.1M
Debt
$404.78M
Equity
$200.81M
Working capital
$438.87M
Liquidity
Debt to equity
2.02
Current ratio
3.47
Quick ratio
3.31
Net debt/EBITDA
-5.65
Margins
EBITDA margin
-42.2%
Gross margin
92.1%
Net margin
-76.7%
Operating margin
-267.2%
Efficiency
Return on assets
-14.1%
Return on equity
-56.7%
Return on invested capital
-12.3%
Return on capital employed
-16.3%
Return on sales
-68.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

TVTX stock price

How has the Travere Therapeutics stock price performed over time
Intraday
1.62%
1 week
19.01%
1 month
-10.32%
1 year
-60.65%
YTD
-30.37%
QTD
-18.81%

Financial performance

How have Travere Therapeutics's revenue and profit performed over time
Revenue
$145.24M
Gross profit
$133.79M
Operating income
-$388.14M
Net income
-$111.4M
Gross margin
92.1%
Net margin
-76.7%
The net margin has soared by 70% year-on-year but it has dropped by 61% since the previous quarter
TVTX's net income has surged by 60% year-on-year but it is down by 28% since the previous quarter
The operating margin has contracted by 42% from the previous quarter but it has grown by 9% YoY
The revenue has increased by 33% year-on-year but it has declined by 21% since the previous quarter

Growth

What is Travere Therapeutics's growth rate over time

Valuation

What is Travere Therapeutics stock price valuation
P/E
N/A
P/B
2.34
P/S
3.2
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.67
The company's EPS has surged by 66% YoY but it fell by 2.7% QoQ
The price to book (P/B) is 66% lower than the 5-year quarterly average of 6.8 and 60% lower than the last 4 quarters average of 5.8
TVTX's equity is down by 28% since the previous quarter
The stock's P/S is 57% below its 5-year quarterly average of 7.4 and 47% below its last 4 quarters average of 6.0
The revenue has increased by 33% year-on-year but it has declined by 21% since the previous quarter

Efficiency

How efficient is Travere Therapeutics business performance
Travere Therapeutics's return on equity has surged by 74% YoY but it has decreased by 2.3% QoQ
The company's return on sales has surged by 72% YoY but it has shrunk by 67% QoQ
The return on invested capital has surged by 66% year-on-year but it has declined by 29% since the previous quarter
The company's return on assets has surged by 62% YoY but it fell by 24% QoQ

Dividends

What is TVTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for TVTX.

Financial health

How did Travere Therapeutics financials performed over time
TVTX's total assets is 34% more than its total liabilities
The quick ratio has decreased by 29% from the previous quarter
The company's current ratio fell by 29% QoQ
The debt is 102% greater than the equity
Travere Therapeutics's debt to equity has plunged by 79% YoY but it has increased by 39% from the previous quarter
TVTX's equity is down by 28% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.